Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - tamoxifen citrate - oral tablet - 20mg

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - tamoxifen citrate - oral tablet - 20mg

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

cp pharmaceuticals ltd. - tamoxifen (tamoxifen citrate) - tablets film-coated - 10mg

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

cp pharmaceuticals ltd. - tamoxifen (tamoxifen citrate) - tablets film-coated - 20mg

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

astrazeneca ab - tamoxifen - film-coated tablet - 20 milligram(s) - anti-estrogens; tamoxifen

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - tamoxifen citrate - tablet - 20 milligram(s) - anti-estrogens; tamoxifen

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - tamoxifen citrate - oral tablet - 20mg

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - toremifene citrate, quantity: 88.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; povidone; maize starch - for the first line treatment of hormone-dependent metastatic breast cancer in postmenopausal women. it is not recommended for patients with oestrogen receptor negative tumours.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - tamoxifen citrate, quantity: 15.2 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; gelatin; hypromellose; macrogol 300; lactose monohydrate; maize starch; magnesium stearate; titanium dioxide - treatment of breast cancer nolvadex is indicated for the treatment of breast cancer. primary reduction of breast cancer risk nolvadex is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

Spojené státy - angličtina - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - toremifene citrate (unii: 2498y783qt) (toremifene - unii:7nfe54o27t) - toremifene citrate tablets are an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. toremifene citrate tablets are contraindicated in patients with known hypersensitivity to the drug. toremifene should not be prescribed to patients with congenital/acquired qt prolongation (long qt syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia. pregnancy category d [see warnings and precautions (5.6)] based on its mechanism of action in humans and findings of increased pregnancy loss and fetal malformation in animal studies, toremifene citrate tablets can cause fetal harm when administered to a pregnant woman. toremifene caused embryo-fetal toxicities at maternal doses that were lower than the 60 mg daily recommended human dose on a mg/m2 basis. there are no adequate and well-controlled studies in pregnant women using toremifene citrate tablets. if this drug is used during pregnancy, or if the patie